Travatan is specifically approved for primary open-angle glaucoma and ocular hypertension. Off-label use for other eye conditions has not been established with sufficient evidence, and any such use should be discussed with an eye-care specialist.
Iris colour change is a known, usually permanent effect of prostaglandin analogues. If the change is concerning or accompanied by other symptoms, schedule an appointment with your ophthalmologist for evaluation.
Contact lenses should be removed before instilling Travatan. Wait at least 15 minutes after dosing before reinserting lenses to avoid drug adsorption onto the lens material.
Certain eye drops, such as non-steroidal anti-inflammatory drops, may diminish Travatan’s effect. Always inform your eye-care provider about all ocular medications you are using.
Travatan begins to reduce intra-ocular pressure within a few hours after administration, with the maximum effect typically observed 8-12 hours later.
After opening, the bottle should be used within 30 days. Discard any remaining solution beyond this period, even if the expiration date on the label is later.
Travatan can be carried in hand luggage in its original container. It is advisable to keep the bottle in a clear, resealable plastic bag and carry a copy of the prescription if requested by security personnel.
Travatan does not impair vision or cognitive function. However, if you experience transient blurred vision after dosing, wait until vision clears before driving.
Systemic absorption of travoprost from eye drops is minimal. Report any unexpected systemic symptoms, such as headaches or respiratory changes, to a healthcare professional.
Travatan is a brand-name formulation; generic travoprost eye drops may be available at a lower price. Pricing can vary by pharmacy and region, and patients should discuss options with their prescriber and pharmacist.
Travatan is a prescription eye-drop medication that contains the active ingredient travoprost. It belongs to the class of prostaglandin-F2α analogues, a group of drugs used to lower intra-ocular pressure (IOP) in conditions such as primary open-angle glaucoma and ocular hypertension. Travatan is supplied in a sterile 2.5 ml bottle of ophthalmic solution and is regulated in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA).
Travoprost is a synthetic analogue of prostaglandin F2α. After the drop is placed on the eye’s surface, the drug is absorbed through the cornea and binds to prostanoid FP receptors in the ciliary muscle. This binding triggers a cascade that increases the outflow of aqueous humor via the uveoscleral pathway, thereby reducing intra-ocular pressure. The medication begins to lower IOP within a few hours, reaches its peak effect after 8-12 hours, and the pressure-lowering effect can last for about 24 hours, allowing once-daily dosing.
Travatan is approved by the MHRA for the following indications:
These conditions are characterized by elevated intra-ocular pressure that can damage the optic nerve and lead to progressive vision loss if untreated. Travatan is intended for adult patients who require a topical therapy to lower IOP and preserve visual function.
Travoprost has a low potential for systemic drug interactions because it is administered locally. However:
This article provides educational information about Travatan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
